Skip to main content
Premium Trial:

Request an Annual Quote

DHMRI Buys Immune Tolerance Institute

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The David H. Murdock Research Institute today announced it has acquired the Immune Tolerance Institute for an undisclosed amount.

The acquisition enhances DHMRI's capabilities to discover novel immunomodulatory therapies and corresponding biomarkers for translation into clinical practice, DHMRI said.

"The acquisition of ITI will allow us to extend the DMHRI's capabilities even further into the pre-clinical and clinical settings, and thus provide increasingly integrated solutions from discovery into development, ultimately improving the health of patients and consumers alike," DMHRI President Mike Luther said in a statement.

Based in Kannapolis, NC, DHMRI provides genomic, proteomic, cellular, and bioinformatics technology platforms to academic and industry partners. ITI is a non-profit based in Menlo Park, Calif., and develops treatments for immune system-related diseases.

Last year, DHMRI and ITI established a research center to speed up discovery and development of treatments for such conditions.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.